Malattie neurodegenerative: il topo è INUTILE


In questo articolo il modello murino è definito “inutile” nella cura delle malattie neurodegenerative.

“”Penso che ci sia un senso di disperazione nel fatto che ci serva un modello utile per portare farmaci alle prove cliniche” […] Ma la disperazione, aggiunge, è una giustificazione inadeguata per continuare ad usare un modello mediocre.”

 “I think there’s a sense of desperation that we need a convenient model for bringing drugs to clinical trial,” says Benatar. “And I do sort of hear that concern.” But desperation, he adds, is an inadequate justification for the continued use of a poor model. “It’s a bit like the proverbial drunk who keeps looking for his lost keys under the lamp post, simply because the light’s better there.”

 “The results of drug tests in mice have never translated perfectly to tests in humans. But in recent years, and especially for neurodegenerative diseases, mouse model results have seemed nearly useless. In the past year, for example, three major Alzheimer’s drug candidates, Alzhemed (3-amino-1-propanesulphonic acid), Flurizan (tarenflurbil) and bapineuzumab, all of which had seemed powerfully effective in mouse models, have performed weakly or not at all in clinical trials involving thousands of human Alzheimer’s patients.”

“In the case of ALS, close to a dozen different drugs have been reported to prolong lifespan in the SOD1 mouse, yet have subsequently failed to show benefit in ALS patients.”

“Alzheimer’s mouse models typically develop amyloid ‘plaques’ in their brains, but they do not develop an Alzheimer’s-like dementia and anti-amyloid strategies have repeatedly failed to slow the disease in clinical trials. Parkinson’s researchers have never had a good mouse model for the full disease process, and even the mouse model for Huntington’s disease — a relatively simple genetic disease — does not fully reproduce the clinical signs seen in humans with the disorder.”

[Schnabel J. Neuroscience: Standard model. Nature. 2008 Aug 7;454(7205):682-5. doi: 10.1038/454682a.]


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:


Stai commentando usando il tuo account Chiudi sessione / Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione / Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione / Modifica )

Google+ photo

Stai commentando usando il tuo account Google+. Chiudi sessione / Modifica )

Connessione a %s...